GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding.
Some results have been hidden because they may be inaccessible to you